Journal
ISCIENCE
Volume 25, Issue 2, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.isci.2021.103694
Keywords
-
Categories
Funding
- Bavarian Ministry of Science and Art
- FOR-COVID
Ask authors/readers for more resources
In this study, the neutralization capacity against the Delta variant of concern (VoC) was significantly increased in sera of participants who received a heterologous ChAdOx1 nCoV-19/BNT162b2 vaccine, especially in women with more severe adverse effects following the second immunization.
Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the recommendations of many countries over homologous vector-based ChAdOx1 nCoV-19 vaccination after reports of thromboembolic events and lower efficacy of this regimen. In the middle of 2021, the SARS-CoV-2 Delta variant of concern (VoC) has become predominant in many countries worldwide. Data addressing the neutralization capacity of a heterologous ChAdOx1 nCoV-19/mRNA-based vaccination approach against the Delta VoC in comparison to the widely used homologous mRNA-based vaccine regimen are limited. Here, we compare serological immune responses of a cohort of ChAdOx1 nCoV-19/ BNT162b2-vaccinated participants with those of BNT162b2/BNT162b2 vaccinated ones and show that neutralization capacity against the Delta VoC is significantly increased in sera of ChAdOx1 nCoV-19/BNT162b2-vaccinated participants. This overall effect can be attributed to ChAdOx1 nCoV-19/BNT162b2-vaccinated women, especially those with more severe adverse effects leading to sick leave following second immunization.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available